Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.
<h4>Background</h4>Acquired myasthenia gravis (MG) is a rare antibody-mediated autoimmune disease caused by impaired neuromuscular transmission, leading to abnormal muscle fatigability. The aetiology is complex, including genetic risk factors of the human leukocyte antigen (HLA) complex...
Guardado en:
Autores principales: | Angelina H Maniaol, Ahmed Elsais, Åslaug R Lorentzen, Jone F Owe, Marte K Viken, Hanne Sæther, Siri T Flåm, Geir Bråthen, Margitta T Kampman, Rune Midgard, Marte Christensen, Anna Rognerud, Emilia Kerty, Nils Erik Gilhus, Chantal M E Tallaksen, Benedicte A Lie, Hanne F Harbo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/edbb9d2aa7fa423cb723be038e69af08 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profound olfactory dysfunction in myasthenia gravis.
por: Fidias E Leon-Sarmiento, et al.
Publicado: (2012) -
Fetal Surveillance in Pregnancies with Myasthenia Gravis
por: Brîndușa Ana Cimpoca-Raptis, et al.
Publicado: (2021) -
PLASMAPHERESIS IN THE TREATMENT OF MYASTHENIA GRAVIS: OUTCOME AND COMPLICATIONS
por: Maryam Abbas, et al.
Publicado: (2021) -
Frontalis sling procedure for ocular myasthenia gravis
por: Isogai N, et al.
Publicado: (2012) -
Current and emerging therapies for the treatment of myasthenia gravis
por: Renato Mantegazza, et al.
Publicado: (2011)